People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aethon Therapeutics, Inc. | — | Biotechnology | Series A | $6.0M | $66.3M | 2022 |
| Deep Apple Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $90.7M | 2021 |
| Red Queen Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $97.4M | 2021 |
Paul Da Silva Jardine at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Da Silva Jardine on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 3 | 19 |
| Spiros Liras | 2 | 6 |
| Michael Ehlers | 1 | 6 |
| Rajesh Chopra | 1 | 2 |
| Brian Shoichet | 1 | 2 |
| Loren Walensky | 1 | 2 |
| William Engels | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.